Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 6/20 | 0.48 |
| ▸ | KLK1 | P06870 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743448 | 1.00 | SYK (0.53) | SYKCTSSCTSLCTSKATM | |
| SCHEMBL4813504 | 0.88 | CTSL (0.58) | CTSSCTSLCTSKATMKLK1 | |
| SCHEMBL21340066 | 0.85 | SYK (0.66) | SYKCTSSCTSLCTSKCTSB | |
| SCHEMBL11127997 | 0.85 | SYK (0.66) | SYKCTSSCTSLCTSKCTSB | |
| SCHEMBL13688643 | 0.85 | SYK (0.66) | SYKCTSSCTSLCTSKCTSB | |
| SCHEMBL5744988 | 0.84 | CTSS (0.56) | SYKCTSSCTSLCTSKATM | |
| SCHEMBL31121703 | 0.82 | BACE1 (0.48) | CTSSCTSKBACE1 | |
| SCHEMBL15279890 | 0.81 | CTSS (0.53) | SYKCTSSCTSLCTSKATM | |
| SCHEMBL6897765 | 0.81 | CTSS (0.62) | SYKCTSSCTSLCTSKATM | |
| SCHEMBL4689227 | 0.80 | CTSS (0.53) | SYKCTSSCTSLCTSKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427423-B9 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | disclosed |
| EP-1427423-B1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | EP | disclosed |
| US-7132416-B2 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050038009-A1 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia | ALBIREO AB (SE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038009-A1 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia | SLC10A2, SLC10A1, ABCB11 | SYK 1552/4885CTSS 3474/4885CTSL 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.